Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement

Journal of the Royal Society Interface

Volumn 11, Issue 93, 2014, Pages

  Goodman, S B ^a,b   Gibon, E ^c,d   Pajarinen, J ^a   Lin, T H ^a   Keeney, M ^a   Ren, P G ^e   Nich, C ^f   Yao, Z ^a   Egashira, K ^g   Yang, F ^a,b   Konttinen, Y T ^h,i  

^a STANFORD UNIVERSITY   (United States)

^b Stanford University   (United States)

^c Paris university   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^f BICHAT HOSPITAL   (France)

^g KYUSHU UNIVERSITY   (Japan)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cell trafficking; Inflammation; Macrophage polarization; NF B; Orthopaedic implants; Wear particles

Indexed keywords

MACROPHAGES; PATHOLOGY; TISSUE;

CELL TRAFFICKING; FOREIGN BODY REACTIONS; INFLAMMATION; MACROPHAGE TRAFFICKING; NUCLEAR FACTOR KAPPAB; ORTHOPAEDIC IMPLANTS; PERIPROSTHETIC OSTEOLYSIS; WEAR PARTICLES;

JOINT PROSTHESES;

CHEMOKINE; CHEMOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; OLIGODEOXYNUCLEOTIDE;

ARTHRALGIA; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; BONE ATROPHY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENZYME INHIBITION; FOREIGN BODY REACTION; GIANT CELL; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; JOINT PROSTHESIS; JOINT SWELLING; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MACROPHAGE POLARIZATION; MEMBRANE DEPOLARIZATION; ORTHOPEDIC IMPLANT; PATHOLOGIC FRACTURE; PHAGOCYTOSIS; PHENOTYPE; PROSTHESIS FAILURE; PROSTHESIS LOOSENING; REVIEW; SYNOVITIS; TARGET CELL; WEAR PARTICLE INDUCED PERIPROSTHETIC OSTEOLYSIS; WOUND HEALING; BIOLOGICAL MODEL; CELL MIGRATION; HIP PROSTHESIS; IMMUNOLOGY; INFLAMMATION; NF-ΚB; ORTHOPAEDIC IMPLANTS; OSTEOLYSIS; PARTICULATE MATTER; PATHOLOGY; WEAR PARTICLES;

CELL TRAFFICKING; INFLAMMATION; MACROPHAGE POLARIZATION; NF-ΚB; ORTHOPAEDIC IMPLANTS; WEAR PARTICLES;

FOREIGN-BODY REACTION; HIP PROSTHESIS; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; OSTEOLYSIS; PARTICULATE MATTER;

EID: 84896913125     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.0962     Document Type: Review

References (136)

1. Goodman SB, Gómez Barrena E, Takagi M, Konttinen YT. 2009 Biocompatibility of total joint replacements: a review. J. Biomed. Mater. Res. A 90, 603-618. (doi:10.1002/jbm.a.32063)
2. Ingham E, Fisher J. 2005 The role of macrophages in osteolysis of total joint replacement. Biomaterials 26, 1271-1286. (doi:10.1016/j.biomaterials.2004. 04.035)
3. Jacobs JJ, Shanbhag A, Glant TT, Black J, Galante JO. 1994 Wear debris in total joint replacements. J. Am. Acad. Orthop. Surg. 2, 212-220.
4. Nich C et al. 2013 Macrophages-key cells in the response to wear debris from joint replacements. J. Biomed. Mater. Res. A 101, 3033-3045. (doi:10.1002/jbm.a.34599)
5. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT. 1994 Macrophage/particle interactions: effect of size, composition and surface area. J. Biomed. Mater. Res. 28, 81-90. (doi:10.1002/jbm.820280111)
6. Goodman SB, Huie P, Song Y, Schurman D, Maloney W, Woolson S, Sibley R. 1998 Cellular profile and cytokine production at prosthetic interfaces: study of tissues retrieved from revised hip and knee replacements. J. Bone Joint Surg. 80, 531-539. (doi:10.1302/0301-620X.80B3.8158)
7. Glant TT et al. 1996 Particulate-induced, prostaglandin- and cytokine-mediated bone resorption in an experimental system and in failed joint replacements. Am. J. Ther. 3, 27-41. (doi:10.1097/00045391-199601000-00006)
8. Tuan RS, Lee FY, Konttinen Y, Wilkinson JM, Smith RL. 2008 What are the local and systemic biologic reactions and mediators to wear debris, and what host factors determine or modulate the biologic response to wear particles? J. Am. Acad. Orthop. Surg. 16(Suppl. 1), S33-S38.
9. Chiba J, Rubash HE. 1994 A biochemical, histologic, and immunohistologic analysis of membranes obtained from failed cemented and cementless total knee arthroplasty. Clin. Orthop. Relat. Res. 299, 114-124. (Pubitemid 24051707)
10. Chiba J, Rubash HE, Kim KJ, Iwaki Y. 1994 The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin. Orthop. Relat. Res. 300, 304-312. (Pubitemid 24085514)
11. Konttinen YT, Zhao D, Beklen A, Ma G, Takagi M, Kivela-Rajamaki M, Ashammakhi N, Santavirta S. 2005 The microenvironment around total hip replacement prostheses. Clin. Orthop. Relat. Res. 430, 28-38. (doi:10.1097/01.blo.0000150451.50452.da)
12. Wang CT, Lin YT, Chiang BL, Lee SS, Hou SM. 2009 Over-expression of receptor activator of nuclear factor-κB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31, 77-82. (doi:10.1016/j.biomaterials.2009.09.017)
13. Kadoya Y, Revell PA, al-Saffar N, Kobayashi A, Scott G, Freeman MA. 1996 Bone formation and bone resorption in failed total joint arthroplasties: histomorphometric analysis with histochemical and immunohistochemical technique. J. Orthop. Res. 14, 473-482. (doi:10.1002/jor.1100140318)
14. Chiu R, Ma T, Smith RL, Goodman SB. 2006 Polymethylmethacrylate particles inhibit osteoblastic differentiation of bone marrow osteoprogenitor cells. J. Biomed. Mater. Res. A 77, 850-856. (doi:10.1002/jbm.a.30697)
15. Chiu R, Ma T, Smith RL, Goodman SB. 2008 Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro. J. Biomed. Mater. Res. A 89, 242-247. (doi:10.1002/jbm.a.32001)
16. Gallo J, Goodman SB, Konttinen YT, Raska M. 2013 Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun. 19, 213-224. (doi:10.1177/1753425912451779)
17. Santavirta S, Konttinen YT, Bergroth V, Eskola A, Tallroth K, Lindholm TS. 1990 Aggressive granulomatous lesions associated with hip arthroplasty: immunopathological studies. J. Bone Joint Surg. Am. 72, 252-258. (Pubitemid 20123696)
18. Maloney WJ, Jasty M, Harris WH, Galante JO, Callaghan JJ. 1990 Endosteal erosion in association with stable uncemented femoral components. J. Bone Joint Surg. Am. 72, 1025-1034. (Pubitemid 20279633)
19. Maloney WJ, Jasty M, Rosenberg A, Harris WH. 1990 Bone lysis in well-fixed cemented femoral components. J. Bone Joint Surg. 72, 966-970. (Pubitemid 20362631)
20. Schwarz EM. 2008 What potential biologic treatments are available for osteolysis? J. Am. Acad. Orthop. Surg. 16(Suppl. 1), S72-S75.
21. Schwarz EM, Looney RJ, O'Keefe RJ. 2000 Anti-TNF-α therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res. 2, 165-168. (doi:10.1186/ar81)
22. Ren PG, Irani A, Huang Z, Ma T, Biswal S, Goodman SB. 2011 Continuous infusion of UHMWPE particles induces increased bone macrophages and osteolysis. Clin. Orthop. Relat. Res. 469, 113-122. (doi:10.1007/s11999-010-1645-5)
23. Gibon E, Ma T, Ren PG, Fritton K, Biswal S, Yao Z, Smith L, Goodman SB. 2012 Selective inhibition of the MCP-1-CCR2 ligand-receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particles. J. Orthop. Res. 30, 547-553. (doi:10.1002/jor.21548)
24. Fritton K, Ren PG, Gibon E, Rao AJ, Ma T, Biswal S, Gambhir SS, Goodman SB. 2012 Exogenous MC3T3 preosteoblasts migrate systemically and mitigate the adverse effects of wear particles. Tissue Eng. A 18, 2559-2567. (doi:10.1089/ten.TEA.2012.0086)
25. Zhang K, Jia TH, McQueen D, Gong WM, Markel DC, Wooley PH, Yang SY. 2009 Circulating blood monocytes traffic to and participate in the periprosthetic tissue inflammation. Inflamm. Res. 58, 837-844. (doi:10.1007/s00011-009-0051-5)
26. Wang H, Jia TH, Zacharias N, Gong W, Du HX, Wooley PH, Wooley PH, Yang S-Y. 2013 Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening. Gene Ther. 20, 128-135. (doi:10.1038/gt.2012.1)
27. Nakashima Y et al. 1999 Induction of macrophage C-C chemokine expression by titanium alloy and bone cement particles. J. Bone Joint Surg. 81, 155-162. (doi:10.1302/0301-620X.81B1.8884)
28. Rao AJ, Gibon E, Ma T, Yao Z, Smith RL, Goodman SB. 2012 Revision joint replacement, wear particles, and macrophage polarization. Acta Biomater. 8, 2815-2823. (doi:10.1016/j.actbio.2012.03.042)
29. Rao AJ, Nich C, Dhulipala LS, Gibon E, Valladares R, Zwingenberger S, Smith RL, Goodman SB. 2013 Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium. J. Biomed. Mater. Res. A 101, 1926-1934. (doi:10.1002/jbm.a.34486)
30. Pajarinen J, Mackiewicz Z, Pollanen R, Takagi M, Epstein NJ, Ma T, Goodman SB, Konttinen YT. 2010 Titanium particles modulate expression of toll-like receptor proteins. J. Biomed. Mater. Res. A 92, 1528-1537. (doi:10.1002/jbm.a.32495)
31. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Maloney WJ, Smith RL, Song Y. 1999 Signaling pathways for tumor necrosis factor-α and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J. Bone Joint Surg. Am. 81, 603-615. (Pubitemid 29241254)
32. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ. 2000 Tumor necrosis factor-α/nuclear transcription factor-κB signaling in periprosthetic osteolysis. J. Orthop. Res. 18, 472-480. (doi:10.1002/jor.1100180321)
33. Ren W, Wu B, Peng X, Mayton L, Yu D, Ren J, Chen BD, Wooley PH. 2006 Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model. J. Orthop. Res. 24, 280-290. (doi:10.1002/jor.20004)
34. Tuan RS, Lee FY, Konttinen TY, Wilkinson JM, Smith RL. 2008 What are the local and systemic biologic reactions and mediators to wear debris, and what host factors determine or modulate the biologic response to wear particles? J. Am. Acad. Orthop. Surg. 16(Suppl. 1), S42-S48.
35. Goodman SB. 2007 Wear particles, periprosthetic osteolysis and the immune system. Biomaterials 28, 5044-5048. (doi:10.1016/j.biomaterials.2007.06.035)
36. Green TR, Fisher J, Matthews JB, Stone MH, Ingham E. 2000 Effect of size and dose on bone resorption activity of macrophages by in vitro clinically relevant ultra high molecular weight polyethylene particles. J. Biomed. Mater. Res. 53, 490-497. (doi:10.1002/1097-4636(200009)53:5〈490::AID-JBM7〉3. 0.CO;2-7)
37. Epstein NJ, Bragg WE, Ma T, Spanogle J, Smith RL, Goodman SB. 2005 UHMWPE wear debris upregulates mononuclear cell proinflammatory gene expression in a novel murine model of intramedullary particle disease. Acta Orthop. 76, 412-420. (Pubitemid 41039360)
38. Goodman SB, Gibon E, Yao Z. 2013 The basic science of periprosthetic osteolysis. Instr. Course Lect. 62, 201-206.
39. Sabokbar A, Pandey R, Quinn JM, Athanasou NA. 1998 Osteoclastic differentiation by mononuclear phagocytes containing biomaterial particles. Arch. Orthop. Trauma Surg. 117, 136-140. (doi:10.1007/s004020050213)
40. Bauer TW. 2002 Particles and periimplant bone resorption. Clin. Orthop. Relat. Res. 405, 138-143. (doi:10.1097/00003086-200212000-00016)
41. Laing KJ, Secombes CJ. 2004 Chemokines. Dev. Comp. Immunol. 28, 443-460. (doi:10.1016/j.dci.2003.09.006)
42. Fernandez EJ, Lolis E. 2002 Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42, 469-499. (doi:10.1146/annurev. pharmtox.42.091901.115838)
43. Goodman SB, Trindade M, Ma T, Genovese M, Smith RL. 2005 Pharmacologic modulation of periprosthetic osteolysis. Clin. Orthop. Relat. Res. 430, 39-45. (doi:10.1097/01.blo.0000149998.88218.05)
44. Deshmane SL, Kremlev S, Amini S, Sawaya BE. 2009 Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313-326. (doi:10.1089/jir.2008.0027)
45. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin J-P, Davenport AP, Spedding M, Harmar AJ. 2005 International union of pharmacology. XLVI. G protein-coupled receptor list. Pharmacol. Rev. 57, 279-288. (doi:10.1124/pr.57. 2.5)
46. Proudfoot AE, Power CA, Wells TN. 2000 The strategy of blocking the chemokine system to combat disease. Immunol. Rev. 177, 246-256. (doi:10.1034/j.1600-065X.2000.17721.x)
47. Huang Z, Ma T, Ren P-G, Smith RL, Goodman SB. 2010 Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. J. Biomed. Mater. Res. A 94, 1264-1269.
48. Yaszay B, Trindade MC, Lind M, Goodman SB, Smith RL. 2001 Fibroblast expression of C-C chemokines in response to orthopaedic biomaterial particle challenge in vitro. J. Orthop. Res. 19, 970-976. (doi:10.1016/S0736-0266(01) 00003-1)
49. Ren PG, Lee SW, Biswal S, Goodman SB. 2008 Systemic trafficking of macrophages induced by bone cement particles in nude mice. Biomaterials 29, 4760-4765. (doi:10.1016/j.biomaterials.2008.09.004)
50. Ren PG, Huang Z, Ma T, Biswal S, Smith RL, Goodman SB. 2010 Surveillance of systemic trafficking of macrophages induced by UHMWPE particles in nude mice by noninvasive imaging. J. Biomed. Mater. Res. A 94, 706-711.
51. Ma T, Huang Z, Ren PG, McCally R, Lindsey D, Smith RL, Goodman SB. 2008 An in vivo murine model of continuous intramedullary infusion of polyethylene particles. Biomaterials 29, 3738-3742. (doi:10.1016/j.biomaterials.2008.05.031)
52. Ma T, Ortiz SG, Huang Z, Ren P, Smith RL, Goodman SB. 2009 In vivo murine model of continuous intramedullary infusion of particles: a preliminary study. J. Biomed. Mater. Res. B Appl. Biomater. 88, 250-253. (doi:10.1002/jbm.b.31175)
53. Gibon E et al. 2012 Effect of a CCR1 receptor antagonist on systemic trafficking of MSCs and polyethylene particle-associated bone loss. Biomaterials 33, 3632-3638. (doi:10.1016/j.biomaterials.2012.02.003)
54. Goodman SB, Yao Z, Keeney M, Yang F. 2013 The future of biologic coatings for orthopaedic implants. Biomaterials 34, 3174-3183. (doi:10.1016/j. biomaterials.2013.01.074)
55. Galli SJ, Borregaard N, Wynn TA. 2011 Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 12, 1035-1044. (doi:10.1038/ni.2109)
56. Ma J, Chen T, Mandelin J, Ceponis A, Miller NE, Hukkanen M, Ma GF, Konttinen YT. 2003 Regulation of macrophage activation. Cell. Mol. Life Sci. 60, 2334-2346. (doi:10.1007/s00018-003-3020-0)
57. Murray PJ, Wynn TA. 2011 Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737. (doi:10.1038/nri3073)
58. Mosser DM, Edwards JP. 2008 Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969. (doi:10.1038/nri2448)
59. Martinez FO, Sica A, Mantovani A, Locati M. 2008 Macrophage activation and polarization. Front. Biosci. 13, 453-461. (doi:10.2741/2692)
60. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. 2010 Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 10, 453-460. (doi:10.1038/nri2784)
61. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004 Interferon-gamma: an overview of signals, mechanisms and functions. J. leukoc. Biol. 75, 163-189. (doi:10.1189/jlb.0603252)
62. Lawrence T, Natoli G. 2011 Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11, 750-761. (doi:10.1038/nri3088)
63. Liu G, Yang H. 2013 Modulation of macrophage activation and programming in immunity. J. Cell. Physiol. 228, 502-512. (doi:10.1002/jcp.24157)
64. Akira S, Takeda K. 2004 Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511. (doi:10.1038/nri1391)
65. Kawai T, Akira S. 2010 The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384. (doi:10.1038/ni.1863)
66. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004 The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686. (doi:10.1016/j.it.2004.09.015)
67. Martinez FO, Helming L, Gordon S. 2009 Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483. (doi:10.1146/annurev.immunol.021908.132532)
68. Gordon S, Taylor PR. 2005 Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964. (doi:10.1038/nri1733)
69. Stein M, Keshav S, Harris N, Gordon S. 1992 Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176, 287-292. (doi:10.1084/jem.176.1.287)
70. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998 The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82. (doi:10.1038/34178)
71. Pascual G et al. 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763. (doi:10.1038/nature03988)
72. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. 2013 Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229, 176-185. (doi:10.1002/path.4133)
73. Auffray C, Sieweke MH, Geissmann F. 2009 Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669-692. (doi:10.1146/annurev.immunol.021908.132557)
74. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP. 2007 The cellular and molecular biology of periprosthetic osteolysis. Clin. Orthop. Relat. Res. 454, 251-261. (doi:10.1097/01.blo.0000238813.95035.1b)
75. Kim KJ, Rubash HE, Wilson SC, D'Antonio JA, McClain EJ. 1993 A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin. Orthop. Relat. Res. 287, 142-152. (Pubitemid 23095045)
76. Xu JW, Konttinen YT, Lassus J, Natah S, Ceponis A, Solovieva S, Aspenberg P, Santavirta S. 1996 Tumor necrosis factor-α (TNF-α) in loosening of total hip replacement (THR). Clin. Exp. Rheumatol. 14, 643-648. (Pubitemid 27013351)
77. Hukkanen M et al. 1997 Aseptic loosening of total hip replacement: macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. J. Bone Joint Surg. Br. 79, 467-474. (doi:10.1302/0301-620X. 79B3.7469)
78. Ishiguro N, Kojima T, Ito T, Saga S, Anma H, Kurokouchi K, Iwahori Y, Iwase T, Iwata H. 1997 Macrophage activation and migration in interface tissue around loosening total hip arthroplasty components. J. Biomed. Mater. Res. 35, 399-406. (doi:10.1002/(SICI)1097-4636(19970605)35: 3〈399::AID-JBM14〉3. 0.CO;2-A)
79. Xu JW, Konttinen YT, Waris V, Patiala H, Sorsa T, Santavirta S. 1997 Macrophage-colony stimulating factor (M-CSF) is increased in the synovial-like membrane of the periprosthetic tissues in the aseptic loosening of total hip replacement (THR). Clin. Rheumatol. 16, 243-248. (doi:10.1007/BF02238958)
80. Watkins SC, Macaulay W, Turner D, Kang R, Rubash HE, Evans CH. 1997 Identification of inducible nitric oxide synthase in human macrophages surrounding loosened hip prostheses. Am. J. Pathol. 150, 1199-1206. (Pubitemid 27152638)
81. Konttinen YT, Xu JW, Waris E, Li TF, Gomez-Barrena E, Nordsletten L, Santavirta S. 2002 Interleukin-6 in aseptic loosening of total hip replacement prostheses. Clin. Exp. Rheumatol. 20, 485-490. (Pubitemid 34846622)
82. Lassus J, Waris V, Xu JW, Li TF, Hao J, Nietosvaara Y, Santavirta S, Konttinen YT. 2000 Increased interleukin-8 (IL-8) expression is related to aseptic loosening of total hip replacement. Arch. Orthop. Trauma Surg. 120, 328-332. (doi:10.1007/s004020050475)
83. Stea S et al. 2000 Cytokines and osteolysis around total hip prostheses. Cytokine 12, 1575-1579. (doi:10.1006/cyto.2000.0753)
84. Takei I, Takagi M, Ida H, Ogino T, Santavirta S, Konttinen YT. 2000 High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. J. Rheumatol. 27, 894-899. (Pubitemid 30389743)
85. Suh KT, Chang JW, Jung JS. 2002 The role of inducible nitric oxide synthase in aseptic loosening after total hip arthroplasty. J. Bone Joint Surg. Br. 84, 753-757. (doi:10.1302/0301-620X.84B5.12314)
86. Goodman SB, Ma T. 2010 Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31, 5045-5050. (doi:10.1016/j.biomaterials. 2010.03.046)
87. Takagi M, Santavirta S, Ida H, Ishii M, Mandelin J, Konttinen YT. 1998 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. Clin. Orthop. Relat. Res. 352, 35-45. (Pubitemid 28326282)
88. Spanogle JP, Miyanishi K, Ma T, Epstein NJ, Smith RL, Goodman SB. 2006 Comparison of VEGF-producing cells in periprosthetic osteolysis. Biomaterials 27, 3882-3887. (doi:10.1016/j.biomaterials.2006.02.035)
89. Koulouvaris P, Ly K, Ivashkiv LB, Bostrom MP, Nestor BJ, Sculco TP, Purdue PE. 2008 Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis. J. Orthop. Res. 26, 106-116. (doi:10.1002/jor.20486)
90. Maitra R, Clement CC, Crisi GM, Cobelli N, Santambrogio L. 2008 Immunogenecity of modified alkane polymers is mediated through TLR1/2 activation. PLoS ONE 3, e2438. (doi:10.1371/journal.pone.0002438)
91. Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS, Lee JY. 2010 Hypoxic stress up-regulates the expression of toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology 129, 516-524. (doi:10.1111/j.1365-2567. 2009.03203.x)
92. Tyson-Capper AJ, Lawrence H, Holland JP, Deehan DJ, Kirby JA. 2013 Metal-on-metal hips: cobalt can induce an endotoxin-like response. Ann. Rheum. Dis. 72, 460-461. (doi:10.1136/annrheumdis-2012-202468)
93. Potnis PA, Dutta DK, Wood SC. 2013 Toll-like receptor 4 signaling pathway mediates proinflammatory immune response to cobalt-alloy particles. Cell. Immunol. 282, 53-65. (doi:10.1016/j.cellimm.2013.04.003)
94. Konttinen YT, Pajarinen J. 2013 Adverse reactions to metal-on-metal implants. Nat. Rev. Rheumatol. 9, 5-6. (doi:10.1038/nrrheum.2012.218)
95. Pearl JI, Ma T, Irani AR, Huang ZN, Robinson WH, Smith RL, Goodman SB. 2011 Role of the toll-like receptor pathway in the recognition of orthopedic implant wear-debris particles. Biomaterials 32, 5535-5542. (doi:10.1016/j. biomaterials.2011.04.046)
96. Greenfield EM, Beidelschies MA, Tatro JM, Goldberg VM, Hise AG. 2010 Bacterial pathogen-associated molecular patterns stimulate biological activity of orthopaedic wear particles by activating cognate toll-like receptors. J. Biol. Chem. 285, 32 378-32 384. (doi:10.1074/jbc.M110.136895)
97. Tatro JM, Taki N, Islam AS, Goldberg VM, Rimnac CM, Doerschuk CM, Stewart MC, Greenfield EM. 2007 The balance between endotoxin accumulation and clearance during particle-induced osteolysis in murine calvaria. J. Orthop. Res. 25, 361-369. (doi:10.1002/jor.20289)
98. Nalepka JL, Lee MJ, Kraay MJ, Marcus RE, Goldberg VM, Chen X, Greenfield EM. 2006 Lipopolysaccharide found in aseptic loosening of patients with inflammatory arthritis. Clin. Orthop. Relat. Res. 451, 229-235. (doi:10.1097/01.blo.0000224050.94248.38)
99. Trindade MC, Nakashima Y, Lind M, Sun DH, Goodman SB, Maloney WJ, Schurman DJ, Lane Smith R. 1999 Interleukin-4 inhibits granulocyte-macrophage colony-stimulating factor, interleukin-6, and tumor necrosis factor-α expression by human monocytes in response to polymethylmethacrylate particle challenge in vitro. J. Orthop. Res. 17, 797-802. (doi:10.1002/jor.1100170602)
100. Im GI, Han JD. 2001 Suppressive effects of interleukin-4 and interleukin-10 on the production of proinflammatory cytokines induced by titanium-alloy particles. J. Biomed. Mater. Res. 58, 531-536. (doi:10.1002/jbm.1051)
101. Pajarinen J, Kouri VP, Jamsen E, Li TF, Mandelin J, Konttinen YT. 2013 The response of macrophages to titanium particles is determined by macrophage polarization. Acta Biomater. 9, 9229-9240. (doi:10.1016/j.actbio.2013.06.027)
102. Antonios JK, Yao Z, Li C, Rao AJ, Goodman SB. 2013 Macrophage polarization in response to wear particles in vitro. Cell. Mol. Immunol. 10, 471-482. (doi:10.1038/cmi.2013.39)
103. Wang Y, Wu NN, Mou YQ, Chen L, Deng ZL. 2013 Inhibitory effects of recombinant IL-4 and recombinant IL-13 on UHMWPE-induced bone destruction in the murine air pouch model. J. Surg. Res. 180, e73-e81. (doi:10.1016/j.jss.2012.04. 016)
104. Trindade MC, Lind M, Goodman SB, Maloney WJ, Schurman DJ, Smith RL. 1999 Interferon-gamma exacerbates polymethylmethacrylate particle-induced interleukin-6 release by human monocyte/macrophages in vitro. J. Biomed. Mater. Res. 47, 1-7. (doi:10.1002/(SICI)1097-4636(199910)47: 1〈1::AID-JBM1〉3. 0.CO;2-8)
105. Schwarz E, Campbell D, Totterman S, Boyd A, O'Keefe R, Looney R. 2003 Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J. Orthop. Res. 21, 1049-55. (doi:10.1016/S0736-0266(03)00093-7)
106. Yang SY, Wu B, Mayton L, Mukherjee P, Robbins P, Evans C, Wooley PH. 2004 Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis. Gene Ther. 11, 483-491. (doi:10.1038/sj.gt.3302192)
107. Wei S, Kitaura H, Zhou P, Ross F, Teitelbaum S. 2005 IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115, 282-290. (Pubitemid 40385470)
108. O'Hare T, Corbin A, Druker B. 2006 Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16, 92-99. (doi:10.1016/j.gde.2005.11.002)
109. Gilmore T, Herscovitch M. 2006 Inhibitors of NF-κB signaling: 785 and counting. Oncogene 25, 6887-6899. (doi:10.1038/sj.onc.1209982)
110. Tas S, Vervoordeldonk M, Tak P. 2009 Gene therapy targeting nuclear factor-κB: towards clinical application in inflammatory diseases and cancer. Curr. Gene Ther. 9, 160-170. (doi:10.2174/156652309788488569)
111. Clohisy J, Yamanaka Y, Faccio R, Abu-Amer Y. 2006 Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J. Orthop. Res. 24, 1358-1365. (doi:10.1002/jor.20184)
112. Mao X, Pan X, Cheng T, Zhang X. 2012 Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model. Inflammation 35, 905-912. (doi:10.1007/s10753-011-9392-7)
113. Osako M, Nakagami H, Morishita R. 2012 Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy. Curr. Top. Med. Chem. 12, 1603-1607. (doi:10.2174/156802612803531397)
114. Dinh TD, Higuchi Y, Kawakami S, Yamashita F, Hashida M. 2011 Evaluation of osteoclastogenesis via NFκB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cytokine production from primary cultured macrophages. Pharm. Res. 28, 742-751. (doi:10.1007/s11095-011- 0366-0)
115. Desmet C et al. 2004 Selective blockade of NF-κB activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 173, 5766-5775. (Pubitemid 39392166)
116. Miyake T, Aoki M, Osako M, Shimamura M, Nakagami H, Morishita R. 2010 Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model. Mol. Ther. 19, 181-187. (doi:10.1038/mt.2010.208)
117. Miyake T, Aoki M, Morishita R. 2008 Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFκB and E2F in a rabbit model. Cardiovasc. Res. 79, 706-714. (doi:10.1093/cvr/cvn139)
118. Miyake T et al. 2006 Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFκB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther. 13, 695-704. (doi:10.1038/sj.gt. 3302704)
119. Nakashima H et al. 2004 Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor κB and ets transcription factors. Circulation 109, 132-138. (doi:10.1161/01.CIR.0000105725.61763.A2)
120. Ogushi I et al. 2003 Nuclear factor κB decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model. Hepatology 38, 335-344. (doi:10.1053/jhep.2003.50298)
121. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y, Morishita R. 2002 Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther. 9, 1221-1229. (doi:10.1038/sj.gt.3301724)
122. Shimizu H, Nakagami H, Morita S, Tsukamoto I, Osako M, Nakagami F, Shimosato T, Minobe N, Morishita R. 2009 New treatment of periodontal diseases by using NF-κB decoy oligodeoxynucleotides via prevention of bone resorption and promotion of wound healing. Antioxid. Redox Signal. 11, 2065-2075. (doi:10.1089/ars.2008.2355)
123. de Poorter J, Tolboom T, Rabelink M, Pieterman E, Hoeben R, Nelissen R, Huizinga TWJ. 2005 Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. J. Gene med. 7, 1421-1428. (doi:10.1002/jgm.795)
124. Ollivere B, Wimhurst J, Clark I, Donell S. 2012 Current concepts in osteolysis. J. Bone Joint Surg. Br. 94, 10-15. (doi:10.1302/0301-620X.94B1. 28047)
125. Shi Y et al. 2013 Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 20, 510-518. (doi:10.1038/cr. 2010.44)
126. Cao S, Zhang X, Edwards J, Mosser D. 2006 NF-κB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 281, 26 041-26 050. (doi:10.1074/jbc.M602222200)
127. Chang J et al. 2013 NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc. Natl Acad. Sci. USA 110, 9469-9474. (doi:10.1073/pnas.1300532110)
128. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang C-Y. 2009 Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat. Med. 15, 682-689. (doi:10.1038/nm.1954)
129. Chen X, Hu C, Wang G, Li L, Kong X, Ding Y, Jin Y. 2013 Nuclear factor-κB modulates osteogenesis of periodontal ligament stem cells through competition with β-catenin signaling in inflammatory microenvironments. Cell Death Dis. 4, e510. (doi:10.1038/cddis.2013.14)
130. Stein B, Baldwin A, Ballard D, Greene W, Angel P, Herrlich P. 1993 Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12, 3879-3891. (Pubitemid 23282764)
131. Lee EG et al. 2000 Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354. (doi:10.1126/science.289.5488.2350)
132. Orozco C, Maalouf NM. 2012 Safety of bisphosphonates. Rheum. Dis. Clin. North Am. 38, 681-705. (doi:10.1016/j.rdc.2012.09.001)
133. McClung M et al. 2013 Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med. 126, 13-20. (doi:10.1016/j.amjmed.2012.06. 023)
134. Schmalzried TP et al. 1992 The mechanism of loosening of cemented acetabular components in total hip arthroplasty: analysis of specimens retrieved at autopsy. Clin. Orthop. Relat. Res. 274, 60-78.
135. Mantovani A, Locati M. 2009 Orchestration of macrophage polarization. Blood 114, 3135-3136. (doi:10.1182/blood-2009-07-231795)
136. Mantovani A, Sica A, Locati M. 2005 Macrophage polarization comes of age. Immunity 23, 344-346. (doi:10.1016/j.immuni.2005.10.001)